Combating acquired resistance to MAPK inhibitors in melanoma by targeting Abl1/2-mediated reactivation of MEK/ERK/MYC signaling
Resistance to BRAF/MEK inhibitors is a major impediment to long-term survival for patients with BRAF-mutant melanomas. Here, the authors show that ABL kinases drive resistance by promoting MEK/ERK reactivation and the FDA-approved ABL kinase inhibitor nilotinib prevents and overcomes resistance.
Guardado en:
| Autores principales: | , , , , , , , , , , , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Nature Portfolio
2020
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/7126349dcc164a17b73b14d99a4c497c |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:7126349dcc164a17b73b14d99a4c497c |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:7126349dcc164a17b73b14d99a4c497c2021-12-02T17:32:58ZCombating acquired resistance to MAPK inhibitors in melanoma by targeting Abl1/2-mediated reactivation of MEK/ERK/MYC signaling10.1038/s41467-020-19075-32041-1723https://doaj.org/article/7126349dcc164a17b73b14d99a4c497c2020-10-01T00:00:00Zhttps://doi.org/10.1038/s41467-020-19075-3https://doaj.org/toc/2041-1723Resistance to BRAF/MEK inhibitors is a major impediment to long-term survival for patients with BRAF-mutant melanomas. Here, the authors show that ABL kinases drive resistance by promoting MEK/ERK reactivation and the FDA-approved ABL kinase inhibitor nilotinib prevents and overcomes resistance.Rakshamani TripathiZulong LiuAditi JainAnastasia LyonChristina MeeksDana RichardsJinpeng LiuDaheng HeChi WangMarika NespiAndrey RymarPeng WangMelissa WilsonRina PlattnerNature PortfolioarticleScienceQENNature Communications, Vol 11, Iss 1, Pp 1-18 (2020) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN |
| topic |
Science Q |
| spellingShingle |
Science Q Rakshamani Tripathi Zulong Liu Aditi Jain Anastasia Lyon Christina Meeks Dana Richards Jinpeng Liu Daheng He Chi Wang Marika Nespi Andrey Rymar Peng Wang Melissa Wilson Rina Plattner Combating acquired resistance to MAPK inhibitors in melanoma by targeting Abl1/2-mediated reactivation of MEK/ERK/MYC signaling |
| description |
Resistance to BRAF/MEK inhibitors is a major impediment to long-term survival for patients with BRAF-mutant melanomas. Here, the authors show that ABL kinases drive resistance by promoting MEK/ERK reactivation and the FDA-approved ABL kinase inhibitor nilotinib prevents and overcomes resistance. |
| format |
article |
| author |
Rakshamani Tripathi Zulong Liu Aditi Jain Anastasia Lyon Christina Meeks Dana Richards Jinpeng Liu Daheng He Chi Wang Marika Nespi Andrey Rymar Peng Wang Melissa Wilson Rina Plattner |
| author_facet |
Rakshamani Tripathi Zulong Liu Aditi Jain Anastasia Lyon Christina Meeks Dana Richards Jinpeng Liu Daheng He Chi Wang Marika Nespi Andrey Rymar Peng Wang Melissa Wilson Rina Plattner |
| author_sort |
Rakshamani Tripathi |
| title |
Combating acquired resistance to MAPK inhibitors in melanoma by targeting Abl1/2-mediated reactivation of MEK/ERK/MYC signaling |
| title_short |
Combating acquired resistance to MAPK inhibitors in melanoma by targeting Abl1/2-mediated reactivation of MEK/ERK/MYC signaling |
| title_full |
Combating acquired resistance to MAPK inhibitors in melanoma by targeting Abl1/2-mediated reactivation of MEK/ERK/MYC signaling |
| title_fullStr |
Combating acquired resistance to MAPK inhibitors in melanoma by targeting Abl1/2-mediated reactivation of MEK/ERK/MYC signaling |
| title_full_unstemmed |
Combating acquired resistance to MAPK inhibitors in melanoma by targeting Abl1/2-mediated reactivation of MEK/ERK/MYC signaling |
| title_sort |
combating acquired resistance to mapk inhibitors in melanoma by targeting abl1/2-mediated reactivation of mek/erk/myc signaling |
| publisher |
Nature Portfolio |
| publishDate |
2020 |
| url |
https://doaj.org/article/7126349dcc164a17b73b14d99a4c497c |
| work_keys_str_mv |
AT rakshamanitripathi combatingacquiredresistancetomapkinhibitorsinmelanomabytargetingabl12mediatedreactivationofmekerkmycsignaling AT zulongliu combatingacquiredresistancetomapkinhibitorsinmelanomabytargetingabl12mediatedreactivationofmekerkmycsignaling AT aditijain combatingacquiredresistancetomapkinhibitorsinmelanomabytargetingabl12mediatedreactivationofmekerkmycsignaling AT anastasialyon combatingacquiredresistancetomapkinhibitorsinmelanomabytargetingabl12mediatedreactivationofmekerkmycsignaling AT christinameeks combatingacquiredresistancetomapkinhibitorsinmelanomabytargetingabl12mediatedreactivationofmekerkmycsignaling AT danarichards combatingacquiredresistancetomapkinhibitorsinmelanomabytargetingabl12mediatedreactivationofmekerkmycsignaling AT jinpengliu combatingacquiredresistancetomapkinhibitorsinmelanomabytargetingabl12mediatedreactivationofmekerkmycsignaling AT dahenghe combatingacquiredresistancetomapkinhibitorsinmelanomabytargetingabl12mediatedreactivationofmekerkmycsignaling AT chiwang combatingacquiredresistancetomapkinhibitorsinmelanomabytargetingabl12mediatedreactivationofmekerkmycsignaling AT marikanespi combatingacquiredresistancetomapkinhibitorsinmelanomabytargetingabl12mediatedreactivationofmekerkmycsignaling AT andreyrymar combatingacquiredresistancetomapkinhibitorsinmelanomabytargetingabl12mediatedreactivationofmekerkmycsignaling AT pengwang combatingacquiredresistancetomapkinhibitorsinmelanomabytargetingabl12mediatedreactivationofmekerkmycsignaling AT melissawilson combatingacquiredresistancetomapkinhibitorsinmelanomabytargetingabl12mediatedreactivationofmekerkmycsignaling AT rinaplattner combatingacquiredresistancetomapkinhibitorsinmelanomabytargetingabl12mediatedreactivationofmekerkmycsignaling |
| _version_ |
1718380126751686656 |